Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With Asthma

Overview

Study to demonstrate that at least one of the two doses of Berodual® (50 µg fenoterol hydrobromide + 20 µg ipratropium bromide and 25 µg fenoterol hydrobromide + 10 µg ipratropium bromide, 1 puff t.i.d.) administered via Respimat® device gives a bronchodilator response which is not inferior to that obtained from one dose of Berodual® (50 µg fenoterol hydrobromide + 21 µg ipratropium bromide, 2 puffs t.i.d.) administered via the MDI (chlorofluorocarbon-metered dose inhaler) with Aerochamber® and that the safety profile is at least as good when paediatric asthma patients are treated for four weeks.

Full Title of Study: “A Randomized, Double-blind Study to Compare the Safety and Efficacy of Berodual® Inhaled Via the Respimat® Device in Two Dosages (50 µg Fenoterol Hydrobromide + 20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide + 10 µg Ipratropium Bromide, 1 Puff t.i.d.) With That of Berodual® Inhaled Via the MDI With Aerochamber® (50 µg Fenoterol Hydrobromide + 21 µg Ipratropium Bromide, 2 Puffs t.i.d.) in Pediatric Patients With Asthma Over a 4 Week Period”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double
  • Study Primary Completion Date: July 1999

Interventions

  • Drug: Berodual® Respimat®, low dose
  • Drug: Berodual® Respimat®, high dose
  • Drug: Berodual® MDI

Arms, Groups and Cohorts

  • Experimental: Berodual® Respimat®, low dose
  • Experimental: Berodual® Respimat®, high dose
  • Active Comparator: Berodual® MDI Aerochamber®

Clinical Trial Outcome Measures

Primary Measures

  • Change in average FEV1 AUC0-1 (FEV1( (Forced expiratory volume in one second) AUC0-1(Area under the curve between 0 and 1 hour ))
    • Time Frame: pre-dose and 5, 30, 60 minutes post-dose on day 29

Secondary Measures

  • Average FEV1 between 0 and 1 hour (FEV1 AUC0-1)
    • Time Frame: pre-dose and 5, 30, 60 minutes post-dose on days 1 and 15
  • Total average FEV1 between 0 and 1 hour (FEV1 AUC0-1)
    • Time Frame: pre-dose and 5, 30, 60 minutes post-dose on day 29
  • FVC (Forced vital capacity)
    • Time Frame: pre-dose and 5, 30, 60 minutes post-dose on days 1, 15 and 29
  • FEV25-75% (mean forced expiratory flow during the middle half of the FVC
    • Time Frame: pre-dose and 5, 30, 60 minutes post-dose on days 1, 15 and 29
  • FEV1max
    • Time Frame: pre-dose and 5, 30, 60 minutes post-dose on days 1 and 29
  • Onset of therapeutic response
    • Time Frame: Days 1 and 29
  • Peak expiratory flow (PEF)
    • Time Frame: pre-dose until day 29
  • Extent of use of rescue bronchodilator medication
    • Time Frame: up to day 29
  • Overall incidence of adverse events
    • Time Frame: up to day 29
  • Occurrence of application induced bronchoconstriction
    • Time Frame: up to day 29
  • Number of patients with clinically significant changes in heart rate
    • Time Frame: pre-dose and 5, 30, 60 minutes post-dose on days 1, 15, 29
  • Number of patients with clinically significant changes in blood pressure
    • Time Frame: pre-dose and 5, 30, 60 minutes post-dose on days 1, 15, 29
  • Number of patients with abnormal findings in physical examination
    • Time Frame: Baseline, day 29

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of bronchial asthma according to the ATS (American Thoracic Society) criteria – Male or female children between 6 and 15 years old – Screening FEV1: 60-90 % of predicted normal. Predicted normal values will be based on the reference values by Cotes – Airway obstruction reversibility: FEV1 should increase ≥ 12% over baseline 30 to 60 minutes after administration of 2 puffs from the Berodual® MDI used with the Aerochamber® – Ability to be trained in proper use of MDI with Aerochamber® and Respimat® – Ability to perform technically satisfactory pulmonary function tests – No hospital admission for an exacerbation and stable dosage of all pulmonary medication in the last four weeks – Parent(s)/legal guardian is able and willing to give written informed consent in accordance with Good Clinical Practice (GCP) and local legislation. The child is willing to give oral consent Exclusion Criteria:

  • Patients with significant disease other than asthma, e.g. history of clinically significant cardiovascular, renal, neurological, hepatic or endocrine dysfunction (e.g. hyperthyreosis). A clinically significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or which may influence the results of the study or the ability of the patient to participate in and complete the study – Tuberculosis with indication for treatment – History of cancer within the last five years – Patients who have undergone thoracotomy – Current psychiatric disorders – History of life threatening pulmonary obstruction, active bronchiectasis, lung fibrosis, AIDS (acquired immunity deficiency syndrome) and cystic fibrosis – Severe bronchial asthma with frequent nocturnal asthma attacks or acute exacerbations induced by recurrent bronchial infections several times per year – An upper or lower respiratory tract infection in the four weeks prior to the screening visit (= Visit 1) or during the 2-week run-in period – Patients with known narrow-angle glaucoma or raised intra-ocular pressure – Patients with known intolerance or hypersensitivity to any of the trial medication including excipients – Patients using oral corticosteroid medication within the last 4 weeks – Patients using leukotriene receptor antagonists and 5-LO (lipoxygenase) inhibitors within the last 4 weeks – Beta-blocker medication – Patients who have taken an investigational drug one month or six half-lives (whichever is greater) prior to the screening visit – Previous participation in the run-in phase of this study – Presence of psycho-social factors in the patient and/or relatives which, at the discretion of the investigator, do not assure compliance with medication, procedures and/or protocol

Gender Eligibility: All

Minimum Age: 6 Years

Maximum Age: 15 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Boehringer Ingelheim
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.